Trial · NCT00795639
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12 | Sitaxsentan | Baseline | 343.0 | Full Range 160 to 442 | Meters (m) |
| Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12 | Placebo | Baseline | 330.5 | Full Range 169 to 456 | Meters (m) |
| Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12 | Sitaxsentan | Change at Week 12 | 13.0 | Full Range -349 to 105 | Meters (m) |
| Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12 | Placebo | Change at Week 12 | 3.0 | Full Range -338 to 104 | Meters (m) |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 4 - Improvement (n=90, 87) | 6 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 4 - Improvement (n=90, 87) | 2 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 4 - No Change (n=90, 87) | 83 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 4 - No Change (n=90, 87) | 84 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 4 - Deterioration (n=90, 87) | 1 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 4 - Deterioration (n=90, 87) | 1 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 8 - Improvement (n=86, 81) | 13 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 8 - Improvement (n=86, 81) | 6 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 8 - No Change (n=86, 81) | 72 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 8 - No Change (n=86, 81) | 73 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 8 - Deterioration (n=86, 81) | 1 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 8 - Deterioration (n=86, 81) | 2 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 12 - Improvement (n=80, 72) | 17 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 12 - Improvement (n=80, 72) | 7 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Sitaxsentan | Week 12 - No Change (n=80, 72) | 63 | participants | |
| Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Classification at Weeks 4, 8 and 12 | Placebo | Week 12 - No Change (n=80, 72) | 64 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00795639/results